U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

MedGen UID:
925836
•Concept ID:
C4288304
•
Neoplastic Process
Synonyms: Recurrent Non-Squamous Non-Small Cell Lung Cancer; Recurrent Non-Squamous Non-Small Cell Lung Carcinoma

Definition

The reemergence of non-squamous non-small cell lung carcinoma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Lung Non-Squamous Non-Small Cell Carcinoma

Professional guidelines

PubMed

EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Nonsquamous Nonsmall Cell Lung Cancer.
Igawa S, Sato Y, Ishihara M, Kasajima M, Kusuhara S, Nakahara Y, Otani S, Fukui T, Katagiri M, Sasaki J, Masuda N
Asian Pac J Cancer Prev 2016;17(7):3249-53. PMID: 27509958
Pemetrexed in the treatment of advanced non-squamous lung cancer.
Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C
Lung Cancer 2009 Nov;66(2):141-9. Epub 2009 Jul 4 doi: 10.1016/j.lungcan.2009.06.006. PMID: 19577816
Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M, Fasola G, Defferrari C, Brianti A, Bello MG, Follador A, Sinaccio G, Pronzato P, Grossi F
Crit Rev Oncol Hematol 2008 Dec;68(3):183-96. Epub 2008 Jul 7 doi: 10.1016/j.critrevonc.2008.05.002. PMID: 18606548

Recent clinical studies

Etiology

Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L).
Wakuda K, Kenmotsu H, Sato Y, Nakamura A, Akamatsu H, Tachihara M, Miura S, Yokoyama T, Mori K, Nakagawa K, Yamamoto N
BMC Cancer 2023 Sep 25;23(1):902. doi: 10.1186/s12885-023-11417-w. PMID: 37749521Free PMC Article
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, Tsao MS, Yatabe Y, Kerr KM
Lung Cancer 2021 Dec;162:42-53. Epub 2021 Sep 15 doi: 10.1016/j.lungcan.2021.09.003. PMID: 34739853
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M
Lancet Oncol 2019 May;20(5):625-635. Epub 2019 Apr 8 doi: 10.1016/S1470-2045(19)30035-X. PMID: 30975627
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.
Lee JS, Lee KH, Cho EK, Kim DW, Kim SW, Kim JH, Cho BC, Kang JH, Han JY, Min YJ, Park K
Lung Cancer 2018 Aug;122:234-242. Epub 2018 May 24 doi: 10.1016/j.lungcan.2018.05.023. PMID: 30032838
Non-small cell lung cancer patients with EML4-ALK fusion gene are insensitive to cytotoxic chemotherapy.
Morodomi Y, Takenoyama M, Inamasu E, Toyozawa R, Kojo M, Toyokawa G, Shiraishi Y, Takenaka T, Hirai F, Yamaguchi M, Taguchi K, Seto T, Sugio K, Ichinose Y
Anticancer Res 2014 Jul;34(7):3825-30. PMID: 24982409

Diagnosis

Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, Tsao MS, Yatabe Y, Kerr KM
Lung Cancer 2021 Dec;162:42-53. Epub 2021 Sep 15 doi: 10.1016/j.lungcan.2021.09.003. PMID: 34739853
Nivolumab induced hypophysitis in a patient with recurrent non-small cell lung cancer.
Kajal S, Gupta P, Ahmed A, Gupta A
Drug Discov Ther 2021 Sep 22;15(4):218-221. Epub 2021 Aug 29 doi: 10.5582/ddt.2021.01006. PMID: 34456195
Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
Sakai T, Udagawa H, Matsumoto S, Yoh K, Nosaki K, Ikeda T, Zenke Y, Kirita K, Niho S, Akimoto T, Goto K, Ishii G
J Cancer Res Clin Oncol 2021 Apr;147(4):1227-1237. Epub 2020 Sep 30 doi: 10.1007/s00432-020-03413-5. PMID: 32997195
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
Cui W, Franchini F, Alexander M, Officer A, Wong HL, IJzerman M, Desai J, Solomon BJ
Lung Cancer 2020 Aug;146:310-317. Epub 2020 Jun 26 doi: 10.1016/j.lungcan.2020.06.030. PMID: 32619782
Non-small cell lung cancer patients with EML4-ALK fusion gene are insensitive to cytotoxic chemotherapy.
Morodomi Y, Takenoyama M, Inamasu E, Toyozawa R, Kojo M, Toyokawa G, Shiraishi Y, Takenaka T, Hirai F, Yamaguchi M, Taguchi K, Seto T, Sugio K, Ichinose Y
Anticancer Res 2014 Jul;34(7):3825-30. PMID: 24982409

Therapy

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Bordenave S, Juan-Vidal O, Menezes J, Reinmuth N, Richardet E, Cheng Y, Mizutani H, Felip E, Zurawski B, Alexandru A, Paz-Ares L, Lu S, John T, Zhang X, Mahmood J, Hu N, De T, Santi I, Penrod JR, Yuan Y, Lee A, Reck M
J Immunother Cancer 2024 Feb 12;12(2) doi: 10.1136/jitc-2023-008189. PMID: 38346853Free PMC Article
First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial.
Kim HR, Sugawara S, Lee JS, Kang JH, Inui N, Hida T, Lee KH, Yoshida T, Tanaka H, Yang CT, Nishio M, Ohe Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Takahashi S, Nakagawa K
Cancer Med 2023 Aug;12(16):17061-17067. Epub 2023 Aug 28 doi: 10.1002/cam4.6348. PMID: 37641544Free PMC Article
MYL-1402O: A Bevacizumab Biosimilar.
Lee A
Target Oncol 2022 Jan;17(1):85-88. Epub 2021 Dec 15 doi: 10.1007/s11523-021-00858-7. PMID: 34910269Free PMC Article
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, Tsao MS, Yatabe Y, Kerr KM
Lung Cancer 2021 Dec;162:42-53. Epub 2021 Sep 15 doi: 10.1016/j.lungcan.2021.09.003. PMID: 34739853
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M
Lancet Oncol 2019 May;20(5):625-635. Epub 2019 Apr 8 doi: 10.1016/S1470-2045(19)30035-X. PMID: 30975627

Prognosis

Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.
Jung HA, Lim J, Choi YL, Lee SH, Joung JG, Jeon YJ, Choi JW, Shin S, Cho JH, Kim HK, Choi YS, Zo JI, Shim YM, Park S, Sun JM, Ahn JS, Ahn MJ, Han J, Park WY, Kim J, Park K
Clin Cancer Res 2022 Oct 3;28(19):4312-4321. doi: 10.1158/1078-0432.CCR-22-0879. PMID: 35838647
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
Cui W, Franchini F, Alexander M, Officer A, Wong HL, IJzerman M, Desai J, Solomon BJ
Lung Cancer 2020 Aug;146:310-317. Epub 2020 Jun 26 doi: 10.1016/j.lungcan.2020.06.030. PMID: 32619782
A phase II study of the combination of docetaxel and bevacizumab for previously treated non-small cell lung cancer.
Shimizu T, Nakagawa Y, Asai Y, Tsujino I, Takahashi N, Gon Y
J Int Med Res 2019 Jul;47(7):3079-3087. Epub 2019 Jun 10 doi: 10.1177/0300060519852202. PMID: 31179803Free PMC Article
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.
Lee JS, Lee KH, Cho EK, Kim DW, Kim SW, Kim JH, Cho BC, Kang JH, Han JY, Min YJ, Park K
Lung Cancer 2018 Aug;122:234-242. Epub 2018 May 24 doi: 10.1016/j.lungcan.2018.05.023. PMID: 30032838
Pemetrexed in the treatment of advanced non-squamous lung cancer.
Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C
Lung Cancer 2009 Nov;66(2):141-9. Epub 2009 Jul 4 doi: 10.1016/j.lungcan.2009.06.006. PMID: 19577816

Clinical prediction guides

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.
Reck M, Ciuleanu TE, Schenker M, Bordenave S, Cobo M, Juan-Vidal O, Reinmuth N, Richardet E, Felip E, Menezes J, Cheng Y, Mizutani H, Zurawski B, Alexandru A, Carbone DP, Lu S, John T, Aoyama T, Grootendorst DJ, Hu N, Eccles LJ, Paz-Ares LG
Eur J Cancer 2024 Nov;211:114296. Epub 2024 Aug 25 doi: 10.1016/j.ejca.2024.114296. PMID: 39270380
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Bordenave S, Juan-Vidal O, Menezes J, Reinmuth N, Richardet E, Cheng Y, Mizutani H, Felip E, Zurawski B, Alexandru A, Paz-Ares L, Lu S, John T, Zhang X, Mahmood J, Hu N, De T, Santi I, Penrod JR, Yuan Y, Lee A, Reck M
J Immunother Cancer 2024 Feb 12;12(2) doi: 10.1136/jitc-2023-008189. PMID: 38346853Free PMC Article
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Shi Y, Lei K, Jia Y, Ni B, He Z, Bi M, Wang X, Shi J, Zhou M, Sun Q, Wang G, Chen D, Shu Y, Liu L, Guo Z, Liu Y, Yang J, Wang K, Xiao K, Wu L, Yi T, Sun D, Kang M, Ma T, Mao Y, Shi J, Tang T, Wang Y, Xing P, Lv D, Liao W, Luo Z, Wang B, Wu X, Zhu X, Han S, Guo Q, Liu R, Lu Z, Zhang J, Fang J, Hu C, Ji Y, Liu G, Lu H, Wu D, Zhang J, Zhu S, Liu Z, Qiu W, Ye F, Yu Y, Zhao Y, Zheng Q, Chen J, Pan Z, Zhang Y, Lian W, Jiang B, Qiu B, Zhang G, Zhang H, Chen Y, Chen Y, Duan H, Li M, Liu S, Ma L, Pan H, Yuan X, Yuan X, Zheng Y, Gao E, Zhao L, Wang S, Wu C
Cancer Commun (Lond) 2021 Sep;41(9):889-903. Epub 2021 Jun 29 doi: 10.1002/cac2.12179. PMID: 34184418Free PMC Article
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
Cui W, Franchini F, Alexander M, Officer A, Wong HL, IJzerman M, Desai J, Solomon BJ
Lung Cancer 2020 Aug;146:310-317. Epub 2020 Jun 26 doi: 10.1016/j.lungcan.2020.06.030. PMID: 32619782
Pemetrexed in the treatment of advanced non-squamous lung cancer.
Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C
Lung Cancer 2009 Nov;66(2):141-9. Epub 2009 Jul 4 doi: 10.1016/j.lungcan.2009.06.006. PMID: 19577816

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...